Regulators: Reckitt's K-Y buy could hurt price competition; Zerbaxa labels causing dosage confusion;

@FiercePharma: Chicken producer Sanderson says FDA's crackdown on antibiotics lacks 'reliable science.' Article | Follow @FiercePharma

@EricPFierce: #FDA blesses Baxter #saline plant in Spain for shipments to U.S. of  0.9% sodium chloride. More | Follow @EricPFierce

@CarlyHFierce: #ICYMI yesterday - Report: Cadila next in line for injectables bulk-up as it nears deal for Claris. Story | Follow @CarlyHFierce

> U.K. regulators have raised concerns that Reckitt Benckiser's planned acquisition of the K-Y brand of personal lubricants from Johnson & Johnson could lead to higher prices. Report

> The FDA says it's warning healthcare professionals that the labels of Merck's ($MRK) Zerbaxa cause confusion over dosages. Report

> GW Pharmaceuticals ($GWPH) has appointed Julian Gangolli as president of its North American division and is relocating its CEO Justin Gover to the U.S. More

> Kirkland & Ellis, the law firm advising Teva ($TEVA)on its Mylan ($MYL) bid, has hit back at Mylan's attempt to disqualify it from doing so, calling the company's effort an antitakeover tactic. More (sub. req.)

Medical Device News

@FierceMedDev: Neuwave Medical reels in $25M for minimally invasive ablation device. Story | Follow @FierceMedDev

@VarunSaxena2: Issue that led to halt of St. Jude TAVR trial no cause for concern, EuroPCR experts say $STJ. More | Follow @VarunSaxena2

@EmilyWFierce: $MDT CEO Omar Ishrak on the company's strategy in #India: Article | Follow @EmilyWFierce

> India developing federal medical device surveillance system. News

> Report: Researchers develop neuron chips to direct movement of robotic prosthetics. More

Biotech News

@FierceBiotech: Amgen's PCSK9 contender lines up for first place in the blockbuster EU race. Story | Follow @FierceBiotech

@JohnCFierce: What's your list of top 5 public biotechs? (Potential, management, smart execution) I'd put $BLUE in that group. Any other suggestions? | Follow @JohnCFierce

> Novartis' duo of COPD drugs clears Phase III on the path to an FDA decision. More

> Otonomy's ear disease drug slips in Phase IIb, but management keeps the faith. Article

And Finally... Roche's ($RHHBY) Genentech has unveiled an eco-friendly 255,000-square-foot office structure, complete with sun-blocking fins that look like DNA. Story